EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacovigilance in Anti-Tuberculosis Therapy: Adverse Drug Reactions, Risk Factors, and Clinical Management—A Mini-Review

Malaika Naeem, Maryam Hameed, Iqra Afzaal, Wardha Zahid, Syeda Mahrukh Fatim, Labiba, Maryam Shafi, Hadia Khursheed, Abu Sulman

Indus Journal of Bioscience Research · 10.03.2026 · 4 (3.1) · 61-65

DOI: 10.70749/ijbr.v4i3.1.3337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indus Journal of Bioscience Research, online erschienen am 10.03.2026. Verfasst von Malaika Naeem und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the significant advances made in the diagnosis and treatment of tuberculosis (TB), TB continues to be one of the most significant causes of morbidity and mortality throughout the world today. Extended multi-drug treatment courses are the key to effective treatment; however, anti-tuberculosis therapy (ATT) is associated with adverse drug reactions (ADRs) that may cause poor adherence, result in drug-resistant tuberculosis, increased anti-tuberculosis therapy costs and may result in some patients dropping out of treatment. Pharmacovigilance, in particular post-marketing surveillance, is an essential activity for early detection, evaluation, reporting and minimization of adverse drug reactions of anti-tuberculosis drugs. Adverse effects that are clinically significant during TB can still be hepatotoxicity, gastrointestinal intolerance, peripheral neuropathy, optic neuritis, ototoxicity, hematological abnormalities and prolonged QT intervals. Recent times have seen the strengthening of pharmacovigilance activities with the implementation of new concepts like active drug safety monitoring and management (aDSM), Pharmacogenomics, Therapeutic drug monitoring, electronic reporting systems and Artificial Intelligence, which enhance medication safety. This narrative review summarizes the recent evidence on pharmacovigilance in anti-tuberculosis therapy, considers adverse drug reactions (ADR) with anti-TB drugs, reviews patient-related risk factors and draws attention to the current strategies for monitoring, prevention and clinical management of anti-TB medicines.

Zitieren

APA

Naeem, M., Hameed, M., Afzaal, I., Zahid, W., Fatim, S. M., Labiba, Shafi, M., Khursheed, H., & Sulman, A. (2026). Pharmacovigilance in Anti-Tuberculosis Therapy: Adverse Drug Reactions, Risk Factors, and Clinical Management—A Mini-Review. Indus Journal of Bioscience Research, 4(3.1), 61-65. https://doi.org/10.70749/ijbr.v4i3.1.3337

Vancouver

Naeem M, Hameed M, Afzaal I, Zahid W, Fatim SM, Labiba, et al. Pharmacovigilance in Anti-Tuberculosis Therapy: Adverse Drug Reactions, Risk Factors, and Clinical Management—A Mini-Review. Indus Journal of Bioscience Research. 2026;4(3.1):61-65. doi:10.70749/ijbr.v4i3.1.3337

BibTeX
@article{Naeem2026,
  author = {Naeem, Malaika and Hameed, Maryam and Afzaal, Iqra and Zahid, Wardha and Fatim, Syeda Mahrukh and Labiba and Shafi, Maryam and Khursheed, Hadia and Sulman, Abu},
  title = {Pharmacovigilance in Anti-Tuberculosis Therapy: Adverse Drug Reactions, Risk Factors, and Clinical Management—A Mini-Review},
  journal = {Indus Journal of Bioscience Research},
  year = {2026},
  volume = {4},
  number = {3.1},
  pages = {61--65},
  doi = {10.70749/ijbr.v4i3.1.3337}
}
Kostenlos starten →